SCHEDULE: Janus Henderson Discloses 9.99% Stake in Tenax Therapeutics

Janus Henderson Group plc has reported a 9.99% passive beneficial ownership stake in Tenax Therapeutics, Inc., totaling 623,733 shares.

Summary

• Janus Henderson Group plc, a global asset manager, has filed a Schedule 13G indicating beneficial ownership in Tenax Therapeutics, Inc.
• The filing reports an aggregate beneficial ownership of 623,733 shares of Tenax Therapeutics' common stock.
• This represents 9.99% of the outstanding common stock of Tenax Therapeutics.
• The ownership includes certain pre-funded and/or common warrants, which are only exercisable within 60 days to the extent that beneficial ownership does not exceed 9.99%.
• An additional 2,658,858 pre-funded and 1,666,660 common warrants are not reflected in the reported figures due to the 9.99% beneficial ownership limitation.
• Janus Henderson Group plc holds shared voting and shared dispositive power over all 623,733 shares.

Sentiment

Score: 7

Explanation: The disclosure of a nearly 10% passive stake by a major asset manager like Janus Henderson Group plc in Tenax Therapeutics is generally viewed positively as it indicates institutional interest and confidence in the company, even if the investment is not intended to influence control.

Positives

• A major institutional investor, Janus Henderson Group plc, has taken a significant 9.99% stake in Tenax Therapeutics, potentially signaling confidence in the company.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

Institutional filings like this Schedule 13G are routine disclosures by large asset managers, indicating their passive investment positions in public companies. Janus Henderson's stake in Tenax Therapeutics reflects a portfolio allocation decision within the broader healthcare or biotechnology sector.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Increased institutional ownership may lend credibility and potentially stability to the stock.
• Management: Awareness of a significant passive institutional holder.

Next Steps

• NA

Key Dates

Recommendation

The filing indicates a significant passive stake by a reputable institutional investor, Janus Henderson Group plc, in Tenax Therapeutics. While this doesn't provide operational or financial performance details, the presence of a large institutional holder can be a positive indicator of long-term interest and potentially provide some stability. However, without further information on the company's fundamentals, pipeline, or market position, a "hold" recommendation is prudent, acknowledging the institutional confidence without overstating its immediate impact.

Keywords

Tenax Therapeutics, Janus Henderson Group, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Investment Adviser, Warrants